Susan Altschuller, Ph.D., MBA

Susan is a seasoned biotechnology executive with over two decades of experience. She was previously Chief Financial Officer of Cerevel Therapeutics, a biotechnology company developing therapies for neuroscience diseases, until its acquisition by AbbVie in August 2024.

Before Cerevel, she was CFO of ImmunoGen, supporting the company’s commercial launch of an antibody-drug conjugate for women with ovarian cancer. Earlier, Dr. Altschuller worked at the rare disease-focused company Alexion, where she led Investor Relations and later Enterprise Finance and held senior finance and investor relations roles at Biogen and Bioverativ, the hemophilia spin-off from Biogen. She began her career as a consultant with the Frankel Group.  Dr. Altschuller currently serves as Audit Chair on the Boards of Vestaron and Refeyn and is a founding Board member of the HNRNP Family Foundation.

Dr. Altschuller holds a BSE in Biomedical Engineering with Honors from Tulane University, a Ph.D. in Biomedical Engineering from the Illinois Institute of Technology, and an MBA from the MIT Sloan School of Management.